Vogenx (NASDAQ:VOGX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, Zacks reports.
Vogenx Stock Performance
Shares of NASDAQ VOGX traded up $0.74 during midday trading on Thursday, reaching $34.13. The stock had a trading volume of 209,756 shares, compared to its average volume of 196,990. Vogenx has a twelve month low of $12.95 and a twelve month high of $36.00.
Analyst Ratings Changes
VOGX has been the topic of a number of research reports. WBB Securities assumed coverage on shares of Vogenx in a report on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 target price on the stock. JonesTrading began coverage on shares of Vogenx in a research note on Tuesday, September 1st. They set a “buy” rating and a $55.00 price target for the company. Finally, Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a report on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat, Vogenx presently has a consensus rating of “Strong Buy” and an average target price of $48.50.
About Vogenx
Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.
The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.
Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.
Further Reading
- Five stocks we like better than Vogenx
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
